دورية أكاديمية
Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples
| العنوان: | Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples |
|---|---|
| المؤلفون: | Tomlins, Scott A, Hovelson, Daniel H, Suga, Jennifer M, Anderson, Daniel M, Koh, Han A, Dees, Elizabeth C, McNulty, Brendan, Burkard, Mark E, Guarino, Michael, Khatri, Jamil, Safa, Malek M, Matrana, Marc R, Yang, Eddy S, Menter, Alex R, Parsons, Benjamin M, Slim, Jennifer N, Thompson, Michael A, Hwang, Leon, Edenfield, William J, Nair, Suresh, Onitilo, Adedayo, Siegel, Robert, Miller, Alan, Wassenaar, Timothy, Irvin, William J, Schulz, William, Padmanabhan, Arvinda, Harish, Vallathucherry, Gonzalez, Anneliese, Mansoor, Abdul Hai, Kellum, Andrew, Harms, Paul |
| المصدر: | Aurora GME |
| بيانات النشر: | Advocate Aurora Health Institutional Repository |
| سنة النشر: | 2021 |
| المجموعة: | Aurora Health Care Digital Repository |
| مصطلحات موضوعية: | Aurora UW Complex General Surgical Oncology Faculty, Oncology |
| الوصف: | Purpose: Tissue-based comprehensive genomic profiling (CGP) is increasingly used for treatment selection in patients with advanced cancer; however, tissue availability may limit widespread implementation. Here, we established real-world CGP tissue availability and assessed CGP performance on consecutively received samples. Materials and methods: We conducted a post hoc, nonprespecified analysis of 32,048 consecutive tumor tissue samples received for StrataNGS, a multiplex polymerase chain reaction (PCR)-based comprehensive genomic profiling (PCR-CGP) test, as part of an ongoing observational trial (NCT03061305). Sample characteristics and PCR-CGP performance were assessed across all tested samples, including exception samples not meeting minimum input quality control (QC) requirements (< 20% tumor content [TC], < 2 mm2 tumor surface area [TSA], DNA or RNA yield < 1 ng/µL, or specimen age > 5 years). Tests reporting ≥ 1 prioritized alteration or meeting TC and sequencing QC were considered successful. For prostate carcinoma and lung adenocarcinoma, tests reporting ≥ 1 actionable or informative alteration or meeting TC and sequencing QC were considered actionable. Results: Among 31,165 (97.2%) samples where PCR-CGP was attempted, 10.7% had < 20% TC and 59.2% were small (< 25 mm2 tumor surface area). Of 31,101 samples evaluable for input requirements, 8,089 (26.0%) were exceptions not meeting requirements. However, 94.2% of the 31,101 tested samples were successfully reported, including 80.5% of exception samples. Positive predictive value of PCR-CGP for ERBB2 amplification in exceptions and/or sequencing QC-failure breast cancer samples was 96.7%. Importantly, 84.0% of tested prostate carcinomas and 87.9% of lung adenocarcinomas yielded results informing treatment selection. Conclusion: Most real-world tissue samples from patients with advanced cancer desiring CGP are limited, requiring optimized CGP approaches to produce meaningful results. An optimized PCR-CGP test, coupled with an inclusive ... |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://institutionalrepository.aah.org/auroragme/21Test |
| DOI: | 10.1200/PO.20.00472 |
| الإتاحة: | https://doi.org/10.1200/PO.20.00472Test https://institutionalrepository.aah.org/auroragme/21Test |
| رقم الانضمام: | edsbas.E6B1E07A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1200/PO.20.00472 |
|---|